TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00722488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
Study: NCT02541799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audio-visual telemedicine
Description: Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
Study: NCT03609671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care + Experimental Individualized Therapy
Description: Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.

Intervention type: OTHER
Group type: OTHER
Intervention: Control: Standard of Care
Description: Participants will undergo standard of care only (no Intervention/no individualized therapy) .
Study: NCT00009789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated conformational radiotherapy
Study: NCT04564950

Intervention type: OTHER
Intervention: Observation of serum and salivary Galectin-3 levels
Description: Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices

Intervention type: OTHER
Intervention: Observation of serum and salivary Galectin-3 levels
Description: Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
Study: NCT01590121

Intervention type: OTHER
Intervention: Aeroplane flight in the past- no active intervention for study
Description: Aeroplane flight(s) previously taken by study participants

Intervention type: OTHER
Intervention: Questionnaire
Description: Flight by aeroplane (previous)
Study: NCT03206047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study: NCT02683057

Intervention type: OTHER
Intervention: International Physical Activity Questionnaire (IPAQ)
Description: all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)

Intervention type: OTHER
Intervention: International Physical Activity Questionnaire (IPAQ)
Description: all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)

Intervention type: OTHER
Intervention: International Physical Activity Questionnaire (IPAQ)
Description: all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
Study: NCT01183208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B
Description: A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention C
Description: A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Study: NCT03059875

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical consultation for a Standardized Geriatric Evaluation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical consultation for a Standardized Geriatric Evaluation
Study: NCT02006121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine hydrochloride
Description: Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 9 mg/ml
Study: NCT01183208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention D
Description: A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention D
Description: A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention E
Description: A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Study: NCT04457102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANIV
Description: mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANIV
Description: mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANIV
Description: mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac

Intervention type: DEVICE
Group type: OTHER
Intervention: MANIV
Description: mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous DIBH
Description: performed on Varian® Halcyon LINAC and Infinity Elekta® linac
Study: NCT04410120

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured 45 minute interviews regarding impact of asthma attacks
Study: NCT00815035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut OIT
Description: Peanut flour that is orally ingested in a graded fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oat flour used as a placebo that is orally ingested a graded fashion
Study: NCT04649827

Intervention type: OTHER
Intervention: Clinical Observation
Description: This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
Study: NCT02672501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences
Study: NCT02059668

Intervention type: BIOLOGICAL
Intervention: Biomarker analyses head & neck cancer tissue, blood specimen
Description: For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
Study: NCT03315286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHADE Ultraviolet Sensor
Description: Patients will wear device for 6 months in addition to their own method of photo-protection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care counseling
Description: Patients will use their own method of photo-protection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care counseling
Description: Patients will use their own method of photo-protection
Study: NCT01641497

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D conformational radiation
Description: 25 \* 1.8 Gy in 5 weeks (=45 Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 25 \* 1.8 Gy in 5 weeks (=45 Gy)
Study: NCT00808639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: intravenously 30mg/m2 over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: intravenously 30mg/ms over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: intravenously 3mg/m2 over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given subcutaneously 24 hours after last chemotherapy dose
Study: NCT00972556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gray Mineral Trioxide Aggregate (GMTA)
Description: Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diluted (20%) Formocresol (DFC)
Description: After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
Study: NCT02991729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad-based decision aid
Description: This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic counseling appointment
Description: All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic counseling appointment
Description: All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
Study: NCT02337452

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Intervention: Web Site
Description: Communicate via family outreach program website
Study: NCT03432793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: oral tablet, QD
Study: NCT04318730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
Study: NCT01238224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: This is an acute study. Tadalafil 20 mg administered prior to a meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: This is an acute study. Tadalafil 20 mg administered prior to a meal
Study: NCT00332683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintaining low (15mmHg) ETT cuff pressure
Description: Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintaining a normal pressure in the ETT cuff
Description: No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
Study: NCT00154310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Tablets orally twice a day to maintain protocol specific target blood levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium
Description: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium
Description: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
Study: NCT02991443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
Study: NCT03148977

Intervention type: PROCEDURE
Intervention: Graft
Description: Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
Study: NCT01291238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthier, Smarter, Happier
Description: Increased physical activity and decreased sugar and fat intake during school hours
Study: NCT00101660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets; oral; 70 mg BID, depending on response
Study: NCT04138342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quantum dots coated with veldoreotide
Description: The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical approved placebo
Description: The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
Study: NCT02086552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Given PO
Study: NCT01948180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: baltaleucel-T
Description: Autologous EBV-specific T-cells
Study: NCT03427190

Intervention type: OTHER
Group type: OTHER
Intervention: APSOM vs Control
Description: In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APSOM vs Control
Description: In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
Study: NCT03495804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol
Description: Experimental group was given polyethylene glycol as oral contrast agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: Active comparator group was given mannitol as oral contrast agent.
Study: NCT00326638

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy
Description: IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~* Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~* Boost IMRT to Prostate 3,200 cGy/16

Intervention type: OTHER
Group type: OTHER
Intervention: Arm A: 3D-Conformal Radiation
Description: 3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16
Study: NCT02321280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Single dose subcutaneous administration
Study: NCT03101241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-8998
Description: T-type calcium channel blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04203537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration during surgery
Study: NCT03592277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
Study: NCT02186080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01543412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
Study: NCT03511417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: over-the-counter hearing device
Description: Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
Study: NCT03432793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: oral tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: oral tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral tablet solution, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral solution, single dose
Study: NCT01908322

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
Study: NCT01781390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPC) 12.5 M
Description: MPC 12.5 M solution for infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPC) 25 M
Description: MPC 25 M solution for infusion.
Study: NCT01351532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation program
Description: cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion